Skip to main content

Compass Therapeutics, Inc.

CMPX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001738021

In the last 90 days, Compass Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 215 institutions reported holding it in 13F filings for Q2 2026, worth $363.4M in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Compass Therapeutics, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of CMPX: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders7376+3
Shares90.5M89.7M−758.3K (−0.8%)
Value$287.7M$176.7M−$110.9M (−38.6%)

New holders (8)

Institutions that held Compass Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to CMPX in Q3 2023
InstitutionSharesValue% of portfolio
Pale Fire Capital SE45,155$89.0K0.01%
Two Sigma Advisers, LP38,600$76.0K0.00%
SG Americas Securities, LLC38,807$76.0K0.00%
Renaissance Technologies LLC26,800$53.0K0.00%
Two Sigma Investments, LP25,700$50.6K0.00%
New Capital Management LP24,243$47.8K0.02%
Verition Fund Management LLC15,515$30.6K0.00%
Principal Financial Group Inc11,972$23.6K0.00%

Sold out (5)

Institutions that held Compass Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.

Institutions that sold out of CMPX in Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
LMR Partners LLP80,692$256.6K
Susquehanna International Group, LLP25,507$81.1K
XTX Topco Ltd10,992$35.0K
State of Wisconsin Investment Board11,601$34.6K
Aquatic Capital Management LLC100$0